Doug Lane, CEO of Applied Integrin Sciences Inc., Will be Giving an Update on the Company’s Progress at the 19th Annual BIO-Europe Conference in Vienna on Nov 4-6, 2013
Westlake Village, CA, October 21, 2013 --(PR.com
)-- Doug Lane will share exciting news about his company’s latest development at the BIO-Europe Conference in Vienna on Nov 4-6, 2013. BIO-Europe is the largest partnering conference in Europe that attracts the global biotechnology industry and has become the ideal setting for the creation of strategic relationships and collaborations between representatives from corporations on the biotechnology value chain. The theme of the 2013 conference is Building Value Through Partnerships.Applied Integrin Sciences, Inc
. discovers, develops and commercializes protein drug therapies for cancer treatments that reduce solid tumor growth and cancer cell progression. These drugs improve patient survival and quality of life. The drug candidates were discovered at the prestigious Norris Cancer Center of the University of Southern California Keck School of Medicine in Los Angeles, California. The scientific team discovered a proprietary drug discovery platform for producing novel, first-in-class protein therapeutics modulating specific integrin receptors known to be involved in cancer growth, progression, and metastasis. These recombinant proteins affect primary tumor, tumor vasculature, and metastatic foci involved in cancer.
Mr. Lane will show the company’s pre-clinical results for its first cancer therapeutic drug candidate that eliminated all intraperitoneal ovarian cancer tumors in a pre-clinical study testing a novel treatment regimen. Funded by the National Cancer Institute through the company's first NCI grant awarded December last year, its lead candidate drug Vicrostatin was combined with a drug-eluting gel and applied into the peritoneum for sustained release of the drug directly to ovarian cancer metastatic tumors.
Doug Lane will also share some insights with some recent experiment that his company is doing with involving the general public in supporting clinical trials. www.whenyouwish.com/boostcancersurvivalrates.